Opinion|Videos|January 12, 2024
Polycythemia Vera: Treatment Goals and Options
Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Divesiran significantly increased the proportion of clinical responders vs placebo in phlebotomy-dependent polycythemia vera.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
5